Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
South Africa
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1h-dibenz(2,3-6,7)oxepino(4,5-c)pyrrole
2. Asenapine
3. Asenapine Maleate
4. Org 5222
5. Org-5222
6. Secuado
7. Trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1h-dibenz(2,3:6,7)oxepino(4,5-c)pyrrole
1. Asenapine Maleate
2. 85650-56-2
3. Asenapine (maleate)
4. Sycrest
5. Asenapine Maleate [usan]
6. Org 5222
7. Org-5222
8. Cu9463u2e2
9. (z)-but-2-enedioic Acid;(2s,6s)-9-chloro-4-methyl-13-oxa-4-azatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),7(12),8,10,14,16-hexaene
10. 1h-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole, 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-, Trans-, (z)-2-butenedioate (1:1)
11. Trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole Maleate
12. Asenapine (as Maleate)
13. (3ars,12brs)-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenzo(2,3:6,7)oxepino(4,5-c)pyrrole (2z)-2-butenedioate (1:1)
14. 1h-dibenz(2,3:6,7)oxepino(4,5-c)pyrrole, 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-, (3ar,12br)-rel-, (2z)-2-butenedioate (1:1)
15. Trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1h-dibenz(2,3:6,7)oxepino(4,5-c)pyrrole Maleate
16. Unii-cu9463u2e2
17. Einecs 288-064-8
18. Saphris (tn)
19. Org 5222 Maleate
20. Asenapine Maleate Solution
21. (s,s)-asenapine Maleate
22. Schembl175228
23. Asenapine Maleate [mi]
24. Asenapine Maleate (jan/usan)
25. Asenapine Maleate [jan]
26. Chebi:71248
27. Asenapine Maleate [mart.]
28. Dtxsid301017360
29. Hms3884e09
30. Asenapine Maleate [who-dd]
31. Asenapine Maleate [ema Epar]
32. Asenapine Maleate, >=98% (hplc)
33. Mfcd00900588
34. S1283
35. Akos015951084
36. Asenapine Maleate [orange Book]
37. Ccg-268667
38. Cs-0859
39. Mk-8274
40. Sch-900274
41. Ac-24116
42. Hy-11100
43. Sw219879-1
44. D02995
45. 650a562
46. Q27139467
47. 65576-45-6, 135883-08-8 (maleic Acid)
48. Asenapine Maleate 1.0 Mg/ml In Methanol (as Free Base)
49. (3as,12bs)-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1h-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole Maleate
50. 1h-dibenz(2,3:6,7)oxepino(4,5-c)pyrrole, 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-,(3ar,12br)-rel-, (2z)-2-butenedioate (1:1)
51. Trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1h-dibenzo[2,3;6,7]-oxepino[4,5-c]pyrrole Maleate
52. Trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrolemaleate
Molecular Weight | 401.8 g/mol |
---|---|
Molecular Formula | C21H20ClNO5 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 2 |
Exact Mass | 401.1030004 g/mol |
Monoisotopic Mass | 401.1030004 g/mol |
Topological Polar Surface Area | 87.1 Ų |
Heavy Atom Count | 28 |
Formal Charge | 0 |
Complexity | 482 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Saphris |
PubMed Health | Asenapine (By mouth) |
Drug Classes | Antipsychotic |
Drug Label | SAPHRIS is a psychotropic agent that is available for sublingual administration. Asenapine belongs to the class dibenzo-oxepino pyrroles. The chemical designation is (3aRS,12bRS)-5-Chloro-2-methyl-2,3,3a,12b-tetrahydro-1Hdibenzo[2,3:6,7]oxepino[4,5-c... |
Active Ingredient | Asenapine maleate |
Dosage Form | Tablet |
Route | Sublingual |
Strength | eq 5mg base; eq 10mg base |
Market Status | Prescription |
Company | Forest Labs |
2 of 2 | |
---|---|
Drug Name | Saphris |
PubMed Health | Asenapine (By mouth) |
Drug Classes | Antipsychotic |
Drug Label | SAPHRIS is a psychotropic agent that is available for sublingual administration. Asenapine belongs to the class dibenzo-oxepino pyrroles. The chemical designation is (3aRS,12bRS)-5-Chloro-2-methyl-2,3,3a,12b-tetrahydro-1Hdibenzo[2,3:6,7]oxepino[4,5-c... |
Active Ingredient | Asenapine maleate |
Dosage Form | Tablet |
Route | Sublingual |
Strength | eq 5mg base; eq 10mg base |
Market Status | Prescription |
Company | Forest Labs |
Sycrest is indicated for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults.
Treatment of bipolar I disorder
Antipsychotic Agents
Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)
N05AH05
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-09-14
Pay. Date : 2013-05-13
DMF Number : 27086
Submission : 2013-05-17
Status : Active
Type : II
NDC Package Code : 65015-817
Start Marketing Date : 2015-01-20
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-10-09
Pay. Date : 2013-05-24
DMF Number : 26785
Submission : 2013-03-08
Status : Active
Type : II
Date of Issue : 2023-04-06
Valid Till : 2026-05-19
Written Confirmation Number : WC-0281
Address of the Firm :
NDC Package Code : 50379-0009
Start Marketing Date : 2012-07-03
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-11-12
Pay. Date : 2013-06-12
DMF Number : 26973
Submission : 2013-03-23
Status : Active
Type : II
NDC Package Code : 50379-0004
Start Marketing Date : 2010-08-05
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-08-28
Pay. Date : 2013-07-30
DMF Number : 27292
Submission : 2013-06-30
Status : Active
Type : II
Date of Issue : 2022-07-27
Valid Till : 2025-07-21
Written Confirmation Number : WC-0087
Address of the Firm :
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-10-01
Pay. Date : 2013-06-25
DMF Number : 27185
Submission : 2013-07-17
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-09-22
Pay. Date : 2013-08-13
DMF Number : 27300
Submission : 2013-08-08
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2024-12-20
Pay. Date : 2024-12-13
DMF Number : 26104
Submission : 2012-05-30
Status : Active
Type : II
NDC Package Code : 17337-0309
Start Marketing Date : 2012-04-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27290
Submission : 2013-07-08
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-09-19
Pay. Date : 2013-08-08
DMF Number : 27194
Submission : 2013-07-04
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27290
Submission : 2013-07-08
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27285
Submission : 2013-12-31
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-11-01
Pay. Date : 2013-05-01
DMF Number : 26923
Submission : 2013-05-16
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-08-28
Pay. Date : 2013-07-30
DMF Number : 27292
Submission : 2013-06-30
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-10-09
Pay. Date : 2013-05-24
DMF Number : 26785
Submission : 2013-03-08
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-11-12
Pay. Date : 2013-06-12
DMF Number : 26973
Submission : 2013-03-23
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2024-12-20
Pay. Date : 2024-12-13
DMF Number : 26104
Submission : 2012-05-30
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-10-01
Pay. Date : 2013-06-25
DMF Number : 27185
Submission : 2013-07-17
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-09-14
Pay. Date : 2013-05-13
DMF Number : 27086
Submission : 2013-05-17
Status : Active
Type : II
Date of Issue : 2022-06-17
Valid Till : 2025-02-07
Written Confirmation Number : WC-0082
Address of the Firm : Karakhadi Plot No. 842-843, At - Karakhdi, Tal. - Padra, Dist - Vadodara 391 450...
Date of Issue : 2022-07-27
Valid Till : 2025-07-21
Written Confirmation Number : WC-0087
Address of the Firm : Plot No.1 to 5, 31 to 35 & 48 to 51, 26 & Kl201, Village Lakhmapur, Taluka Dindo...
Date of Issue : 2023-04-06
Valid Till : 2026-05-19
Written Confirmation Number : WC-0281
Address of the Firm : Sy.No.224/A, Bibinagar (V&M), Yadadri Bhuvanagiri (Dist), Telangana State, Pinco...
NDC Package Code : 53296-0104
Start Marketing Date : 2011-04-19
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (75kg/75kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 50379-0004
Start Marketing Date : 2010-08-05
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 50379-0009
Start Marketing Date : 2012-07-03
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 17337-0309
Start Marketing Date : 2012-04-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65015-817
Start Marketing Date : 2015-01-20
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 55111-937
Start Marketing Date : 2013-01-28
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
About the Company : Inke S.A., is focused since 1980 in the development and manufacture of the highest quality Active Pharmaceutical Ingredients (APIs) with complex synthesis processes for diverse the...
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
About the Company : Acura Labs is one of the fastest-growing pharmaceutical companies backed by a solid and innovative R&D facility and a top-notch Active Pharmaceutical Ingredients (APIs) manufacturi...
About the Company : Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutica...
About the Company : More than 35 years of dedication to quality, service and pursuit of excellence, CHEMO was founded by Hugo Sigman, M.D., and Silvia Gold, Biochemist, in Spain (Barcelona), in 1977, ...
About the Company : Globofarm International Pvt Ltd is a well-informed, highly efficient, Swiftly functioning competitive sourcing entity. We serve private, institutional, and corporate clients worldw...
About the Company : Founded in 2003, Hyderabad-based MSN Labs is one of the fastest-growing research-based pharmaceutical company in India. Boasting a diverse product portfolio, with multiple products...
About the Company : We produce Active Pharmaceutical Ingredients (APIs) providing integrated full-service capabilities. Olon’s ability to develop and manufacture Active Pharmaceutical Ingredients (...
About the Company : Shouyuan chemical (one of the leading chemicals supplier in China) specializes in manufacturing, supplying, and custom synsthesis latest chemicals. Our products cover all kinds of ...
About the Company : In November 2020, Viatris was formed through the combination of Mylan and Upjohn, with a mission of empowering people worldwide to live healthier at every stage of life. Viatris (N...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Saphris-Generic (asenapine) is a USFDA approved atypical antipsychotic that acts as Serotonin 2a (5-HT2a) & D2 receptor antagonist which is indicated for the treatment of schizophrenia & bipolar I disorder.
Lead Product(s): Asenapine Maleate
Therapeutic Area: Psychiatry/Psychology Brand Name: Saphris-Generic
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 03, 2021
Lead Product(s) : Asenapine Maleate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Saphris-Generic (asenapine) is a USFDA approved atypical antipsychotic that acts as Serotonin 2a (5-HT2a) & D2 receptor antagonist which is indicated for the treatment of schizophrenia & bipolar I disorder.
Product Name : Saphris-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 03, 2021
Details:
Saphris-Generic (asenapine) is a USFDA approved atypical antipsychotic that acts as Serotonin 2a (5-HT2a) & D2 receptor antagonist which is indicated for the treatment of schizophrenia & bipolar I disorder.
Lead Product(s): Asenapine Maleate
Therapeutic Area: Psychiatry/Psychology Brand Name: Saphris-Generic
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 12, 2020
Lead Product(s) : Asenapine Maleate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Saphris-Generic (asenapine) is a USFDA approved atypical antipsychotic that acts as Serotonin 2a (5-HT2a) & D2 receptor antagonist which is indicated for the treatment of schizophrenia & bipolar I disorder.
Product Name : Saphris-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 12, 2020
Details:
SECUADO achieved the primary endpoint, demonstrating statistically significant improvement in Positive and Negative Syndrome Scale (PANSS) total score change from baseline to Week 6 compared to placebo.
Lead Product(s): Asenapine Maleate
Therapeutic Area: Psychiatry/Psychology Brand Name: Secuado
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 15, 2020
Lead Product(s) : Asenapine Maleate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Results from Pivotal, Phase 3 Trial for SECUADO® (asenapine) Published in Journal of Clinical Psy...
Details : SECUADO achieved the primary endpoint, demonstrating statistically significant improvement in Positive and Negative Syndrome Scale (PANSS) total score change from baseline to Week 6 compared to placebo.
Product Name : Secuado
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 15, 2020
Details:
The approved ANDA is therapeutically equivalent to the reference listed drug product, Saphris Sublingual Tablets, 5 mg and 10 mg, of Allergan. Asenapine is an atypical antipsychotic indicated for bipolar I disorder as adjunctive treatment to lithium or valproate in adults.
Lead Product(s): Asenapine Maleate
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 12, 2020
Lead Product(s) : Asenapine Maleate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The approved ANDA is therapeutically equivalent to the reference listed drug product, Saphris Sublingual Tablets, 5 mg and 10 mg, of Allergan. Asenapine is an atypical antipsychotic indicated for bipolar I disorder as adjunctive treatment to lithium or v...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 12, 2020
Details:
LTS grants to LIVZON and its Affiliates an exclusive royalty-bearing, sublicensable right and license to jointly develop with LTS the Asenapine TTS and commercialize the Asenapine TTS for the treatment of schizophrenia in China (including Hong Kong and Macau).
Lead Product(s): Asenapine Maleate
Therapeutic Area: Psychiatry/Psychology Brand Name: Asenapine TTS
Study Phase: PreclinicalProduct Type: Other Small Molecule
Sponsor: Livzon Pharmaceutical Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 07, 2020
Lead Product(s) : Asenapine Maleate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Livzon Pharmaceutical Group
Deal Size : Undisclosed
Deal Type : Collaboration
Details : LTS grants to LIVZON and its Affiliates an exclusive royalty-bearing, sublicensable right and license to jointly develop with LTS the Asenapine TTS and commercialize the Asenapine TTS for the treatment of schizophrenia in China (including Hong Kong and M...
Product Name : Asenapine TTS
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 07, 2020
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
11
PharmaCompass offers a list of Asenapine Maleate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Asenapine Maleate manufacturer or Asenapine Maleate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Asenapine Maleate manufacturer or Asenapine Maleate supplier.
PharmaCompass also assists you with knowing the Asenapine Maleate API Price utilized in the formulation of products. Asenapine Maleate API Price is not always fixed or binding as the Asenapine Maleate Price is obtained through a variety of data sources. The Asenapine Maleate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Asenapine Maleate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Asenapine Maleate, including repackagers and relabelers. The FDA regulates Asenapine Maleate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Asenapine Maleate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Asenapine Maleate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Asenapine Maleate supplier is an individual or a company that provides Asenapine Maleate active pharmaceutical ingredient (API) or Asenapine Maleate finished formulations upon request. The Asenapine Maleate suppliers may include Asenapine Maleate API manufacturers, exporters, distributors and traders.
click here to find a list of Asenapine Maleate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Asenapine Maleate DMF (Drug Master File) is a document detailing the whole manufacturing process of Asenapine Maleate active pharmaceutical ingredient (API) in detail. Different forms of Asenapine Maleate DMFs exist exist since differing nations have different regulations, such as Asenapine Maleate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Asenapine Maleate DMF submitted to regulatory agencies in the US is known as a USDMF. Asenapine Maleate USDMF includes data on Asenapine Maleate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Asenapine Maleate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Asenapine Maleate suppliers with USDMF on PharmaCompass.
A Asenapine Maleate written confirmation (Asenapine Maleate WC) is an official document issued by a regulatory agency to a Asenapine Maleate manufacturer, verifying that the manufacturing facility of a Asenapine Maleate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Asenapine Maleate APIs or Asenapine Maleate finished pharmaceutical products to another nation, regulatory agencies frequently require a Asenapine Maleate WC (written confirmation) as part of the regulatory process.
click here to find a list of Asenapine Maleate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Asenapine Maleate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Asenapine Maleate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Asenapine Maleate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Asenapine Maleate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Asenapine Maleate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Asenapine Maleate suppliers with NDC on PharmaCompass.
Asenapine Maleate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Asenapine Maleate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Asenapine Maleate GMP manufacturer or Asenapine Maleate GMP API supplier for your needs.
A Asenapine Maleate CoA (Certificate of Analysis) is a formal document that attests to Asenapine Maleate's compliance with Asenapine Maleate specifications and serves as a tool for batch-level quality control.
Asenapine Maleate CoA mostly includes findings from lab analyses of a specific batch. For each Asenapine Maleate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Asenapine Maleate may be tested according to a variety of international standards, such as European Pharmacopoeia (Asenapine Maleate EP), Asenapine Maleate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Asenapine Maleate USP).